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Abstract: RNA viruses are highly successful pathogens and are the causative agents for many
important diseases. To fully understand the replication of these viruses it is necessary to address the
roles of both positive-strand RNA ((+)RNA) and negative-strand RNA ((−)RNA), and their interplay
with viral and host proteins. Here we used branched DNA (bDNA) fluorescence in situ hybridization
(FISH) to stain both the abundant (+)RNA and the far less abundant (−)RNA in both hepatitis C
virus (HCV)- and Zika virus-infected cells, and combined these analyses with visualization of viral
proteins through confocal imaging. We were able to phenotypically examine HCV-infected cells in
the presence of uninfected cells and revealed the effect of direct-acting antivirals on HCV (+)RNA,
(−)RNA, and protein, within hours of commencing treatment. Herein, we demonstrate that bDNA
FISH is a powerful tool for the study of RNA viruses that can provide insights into drug efficacy and
mechanism of action.
Keywords: hepatitis C virus; Zika virus; positive-sense; negative-sense; direct acting antivirals;
RNA FISH

1. Introduction
Positive-strand RNA, (+)RNA, viruses include many human pathogens, such as the families
picornaviridae (e.g., poliovirus [1]), togaviridae (e.g., rubella virus [2]), and flaviviridae (e.g., Dengue
virus [3], Zika virus [4], and hepatitis C virus [5]). While these viruses pursue a wide range of replication
strategies in diverse hosts, they also share key features and are defined by their use of a (+)RNA
Viruses 2019, 11, 1039; doi:10.3390/v11111039
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genome. This genomic RNA fulfils three distinct functions: (1) it is the mRNA from which proteins are
produced; (2) it is the template from which the negative-strand RNA ((−)RNA) is transcribed, to serve
as the replicative intermediate; and (3) it codes the genetic information that must be packaged into
assembling particles and transferred to target cells. At any given time, an infected cell will contain
many (+)RNA molecules performing these roles, although any single (+)RNA molecule may only
function in one capacity at one time. As the (+)RNA molecules are identical to one another, they cannot
be differentiated by sequence and their separate roles can only be determined through simultaneous
analysis of the interacting cofactors.
Following infection of a target cell, the viral RNA first serves as mRNA, exploiting the host-cell
translational machinery to direct synthesis of the viral proteins; these proteins include enzymes that
are responsible for synthesis of first the negative, then the positive strand of the genome, and proteins
that modify the environment of the cell to support viral replication. Positive-strand RNA viruses
replicate their genomes in the cytoplasm of infected cells, in association with virus-induced membrane
structures, often termed the “membranous web” [6]. These membranes provide a foundation on which
to anchor the viral replication complex (RC), and in combination with viral proteins, may provide
protection against surveillance by the innate immune system. In the RC, the virus synthesizes new
(+)RNA. At early times post-infection, the new (+)RNA will be used to generate more viral proteins and
(−)RNA; at later time points, (+)RNA is packaged into particles made up of the viral structural proteins,
and released from the cell. To better understand the replication of these viruses, their interactions with
the host cell, and ultimately, how to combat them, it is necessary to consider both (+) and (−)RNA, and
their interaction with proteins, viral and cellular.
While there are thousands of antibodies available to specifically identify viral and cellular proteins,
and sufficient fluorescent tags to allow co-visualization of multiple proteins in a single sample, these
imaging approaches are often incompatible with conventional methods for visualization of nucleic
acids (e.g., hybridization of fluorescently labeled oligonucleotide probes). Branched DNA (bDNA) in
situ hybridization is a technique that exploits sequence specific probes, and branching preamplifier and
amplifier DNAs, to produce an intense localized signal [7]. Unlike conventional FISH methods, bDNA
FISH is readily compatible with immunofluorescence, allowing simultaneous analysis of nucleic acids
and proteins (Figure 1). Various bDNA approaches have been developed for commercial use, including
RNAscope [8], PrimeFlow [9], and ViewRNA [10]. These techniques have been applied to quantify
and localize specific nucleic acids and the cells that harbor them. The compatibility of PrimeFlow with
flow cytometry has proven particularly useful for analysis of human immunodeficiency virus (HIV)-1
latency and reservoirs [11–13], while RNAscope and ViewRNA have been employed diagnostically for
histological staining [14–19], and in cell biology to visualize cellular and viral RNAs [20–22]. These
techniques have frequently been employed in low resolution imaging approaches, such as histology
and flow cytometry, that exploit the robust signal to clearly identify rare infected cells. A variation
on the robust detection of an abundant RNA in rare cells is the detection of less abundant targets;
these FISH methods have sufficient sensitivity to identify individual nucleic acid molecules, sometimes
referred to as single molecule FISH. One such application of this sensitivity has been to modify the
experimental conditions to achieve labelling of the viral nucleic acids in HIV-infected cells [22–25].
Most infected cells in the clinical context only contain a small number of integrated proviruses, typically
just one [26]; thus, the signal amplification of bDNA FISH renders it ideally suited to the visualization
of such a low abundance target.
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Figure 1. Schematic of the viral molecules in hepatitis C virus (HCV)-infected cells, and the signal
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2. Materials and Methods
2. Materials and Methods
2.1. Cells and Viruses
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cells are derived from the human hepatoma 7 cell line, and have been previously
described
[34]. Cells
propagated
Dulbecco’s
modified Eagle’s
medium
(DMEM,
Huh-7.5.1
cells were
are derived
frominthe
human hepatoma
7 cell line,
and have
beenInvitrogen,
previously
Carlsbad,
CA,
USA)
supplemented
with
10%
fetal
bovine
serum
(FBS).
Vero-E6
cells
wereInvitrogen,
obtained
described [34]. Cells were propagated in Dulbecco’s modified Eagle’s medium (DMEM,
from
ATCCCA,
andUSA)
cultured
in DMEM with
supplemented
with 10%
FBS.
VeroVero-E6
cells arecells
derived
the
Carlsbad,
supplemented
10% fetal bovine
serum
(FBS).
werefrom
obtained
kidney
of
an
African
green
monkey
and
lack
the
genes
coding
type
I
interferon,
making
them
suitable
from ATCC and cultured in DMEM supplemented with 10% FBS. Vero cells are derived from the
for
the growth
of manygreen
viruses
[35–37].
Jc1-FLAG2(p7-nsGluc2A),
hereafter
Jc1/Gluc2A,
described
kidney
of an African
monkey
and
lack the genes coding type
I interferon,
makingwas
them
suitable
previously
[38]. Zika
MR766)
[39,40]
was obtained from Alexander
Franz
(Universitywas
of
for the growth
of virus
many(isolate
viruses
[35–37].
Jc1-FLAG2(p7-nsGluc2A),
hereafter
Jc1/Gluc2A,
Missouri),
and
propagated
and
titered
in
Vero
cells.
described previously [38]. Zika virus (isolate MR766) [39,40] was obtained from Alexander Franz
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2.2. Compounds and Antibodies
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The initial reverse transcription step of the HCV 5’ UTR was carried out as previously described
[42]. Briefly, total RNA was extracted using an RNeasy kit (Qiagen, Hilden, Germany), and quantified
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absorbance at 260 nm. A quantity of 50 ng of RNA was denatured at 70 ◦ C for 8 min with dNTPs and
either the RC21 primer 50 -CTCCCGGGGCACTCGCAAGC-30 (for the positive strand) or the tag-RC1
primer 50 -ggccgtcatggtggcgaataaGCCTAGCCATGGCGTTAGTA-30 (for the negative strand), followed
by incubation at 4 ◦ C for 5 min. ThermoscriptTM reverse transcriptase (Invitrogen) was added to the
denatured RNA template and incubated at 60 ◦ C for 1 h, followed by RNase H treatment for 20 min at
37 ◦ C. Reverse transcribed cDNA was mixed with RC1 (50 -GCCTAGCCATGGCGTTAGTA-30 ) and
RC21 primers for positive strand amplification and tag (50 -ggccgtcatggtggcgaataa-30 ) and RC21 primers
for negative strand amplification. Amplification was conducted by denaturation at 95 ◦ C for 10 min,
followed by 40 cycles of denaturation at 95 ◦ C for 15 s and annealing/extension at 60 ◦ C for 1 min using
PerfeCTa SYBR Green FastMix (Quanta Biosciences, Beverly, MA, USA). Amplification was carried out
in an Applied Biosystems®® 7500 Fast Real-Time PCR Instrument (ABI). In vitro transcribed RNA
from the HCV infectious clone was used to generate a standard curve.
ZIKV RT-qPCR was performed using the same general approach, with the following
differences. RC21 and RC1 were replaced by Tag-ZK21 primer (50 -ggccgtcatggtggcgaataa
CCTGACAACACTAAaATTGGTGC-30 ) and Tag-ZK1 primer (50 -ggccgtcatggtggcgaataa
AGGATCATAGGTGATGAAGAAAAGT-30 ). cDNA synthesis was performed using SuperScript
III First-Strand Synthesis System (Invitrogen), following the manufacturers’ instructions. qPCR
amplification was conducted using PowerUp SYBR Green Master Mix (Applied Biosystems, Foster
City, CA, USA), in a PikoReal 96 Real-Time PCR system (ThermoFisher Scientific). The cycle conditions
were uracil-DNA glycosylase (UDG) activation at 50 ◦ C for 2 min, dual-lock DNA polymerase at 95 ◦ C
for 2 min, followed by 40 cycles of denaturation at 95 ◦ C for 15 sec, annealing at 55 ◦ C for 15 sec, and
extension at 72 ◦ C for 1 min. An MR766 infectious clone [43] was used to generate a standard curve,
and was subject to the same strand specific RT-qPCR protocol.
2.4. Branched DNA In Situ Hybridization (bDNA FISH) for Strand-Specific Nucleic Acid Visualization
bDNA FISH for cultured adherent cells was used for HCV RNA detection using the RNAscope
method, with some modifications [8]. Cells were fixed in 4% paraformaldehyde for 30 min at room
temperature (RT), washed three time in phosphate buffered saline (PBS), then incubated in PBS
supplemented with 0.1% Tween-20 (PBS-T) for 10 min at RT, followed by two wash steps with PBS.
Coverslips were immobilized on Superfrost glass slides using a small drop of nail polish. A circle
was drawn around the coverslip using an ImmEdge hydrophobic barrier pen (Vector Laboratories).
Protease treatment (Protease 3) was diluted 1:15 in PBS and incubated on the sample in a humidified
HybEZ oven at 40 ◦ C for 15 min and washed twice in PBS. Specific V-HCV-GT2a probe for (+)RNA
(Catalogue number, 441361; Advanced Cell Diagnostics, Newark, CA, USA) was added to the coverslip
and incubated in humidified HybEZ oven at 40 ◦ C for 2 h, followed by HCV-GT2a-sense-C2 probe for
(−)RNA (Catalogue number, 441371) diluted 1:50 in probe dilution buffer for an additional 2 h. Probes
were used sequentially rather than simultaneously because they target the same region of the viral
genome (Table 1) and would likely anneal to one another if applied together. Two consecutive wash
steps were performed in 1× wash buffer (Catalog number, 310091; Advanced Cell Diagnostics) with
agitation at RT for 2 min in every wash step after this point, and all incubations were performed in a
humidified HybEZ oven at 40 ◦ C. bDNA amplification was performed using a series of amplifiers
(RNAscope; Advanced Cell Diagnostics). Amplifier hybridization 1-Fluorescent (Amp 1-FL) was added
to the coverslip for 30 min, followed by Amp 2-FL hybridization for 15 min. Amp 3-FL hybridization
was then added for 30 min, followed by Amp 4-FL hybridization for 15 min. If samples were to be
stained by immunofluorescence, this was performed after the RNAscope staining. Anti-NS5A antibody
and anti-HCV core antibody were diluted 1:1000 in PBS-T, and incubated on coverslips for 1 h at
RT. Secondary anti-mouse Alexa Fluor 647 was diluted 1:2000 in PBS-T and incubated on coverslips
for 1 h at RT. Nuclei were stained with DAPI for 1 min or Hoechst 33258 at 0.5 µg/mL for 10 min at
room temperature in PBS-T. Coverslips were washed 3 times in PBS-T after each incubation. Finally,
coverslips were detached and mounted on fresh slides using ProLong Gold Antifade reagent (Thermo
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Fisher Scientific, Waltham, MA, USA). Most images were obtained using a Leica TCP SP8 MP confocal
fluorescence equipped with a 63× HC PL APO CS2 oil-immersion objective (numerical aperture 1.4),
and a tunable supercontinuum white light laser. The excitation/emission bandpass wavelengths used
to detect DAPI, Alexa 488, ATTO 550, and Alexa 647 were set to 405/420–480, 488/505–550, 550/560–610,
568/580–630, and 647/655–705 nm, respectively. Pixel size under these conditions was 0.18 µm. Within
9, x FORconditions
PEER REVIEW
6 of
18
anyViruses
given2017,
dataset,
such as the laser intensity, exposure time and pinhole were kept
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to allow comparison of the images. Images of the HCV-infected cells for Figure 2 were captured using
for both strands simultaneously, either (+)RNA then (−)RNA, or (−)RNA then (+)RNA (Figure 2B).
a Nikon
C2 confocal microscope, with a 60× APO oil-immersion objective (numerical aperture 1.4).
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in both
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enlarged. Scale bars represent 10 µm.
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Table 1. Probes used in branched DNA fluorescence in situ hybridization (bDNA FISH). All probes
were purchased from ACDBio. HCV, hepatitis C virus; ZIKV, Zika virus.
Nucleic Acid Target

Probe Name

Catalog#

Target Region of Genome
(Coded Protein)

HCV (+)RNA
HCV (−)RNA
ZIKV (+)RNA
ZIKV (−)RNA

V-HCV-GT2a
HCV-GT2a-sense-C2
V-ZIKA-pp-O2
V-ZIKA-pp-O2-sense-C2

441361
441371
464531
478731-C2

4268–5505 (NS3-NS4B)
4268–5505 (NS3-NS4B)
866–1763 (M-E)
866–1763 (M-E)

ZIKV-infected cells were stained by the same protocol as HCV, with the following changes:
the protease pre-treatment used a 1:2 dilution, rather than 1:15; and the ZIKV-specific probes were
V-ZIKA-pp-O2 for the (+)RNA (Catalogue number, 464531) and V-ZIKA-pp-O2-sense-C2 for the
(−)RNA (Catalogue number, 478731-C2).
In order to quantify the differential drug effects on (+) and (−) strands of HCV RNA, we manually
acquired 30 images of each biological replicate drug treatment experiment and performed cellular
analysis and image analysis using BioTek Gen5 software. Abundance of (+) and (−)RNA was quantified
and plotted in two ways: number of fluorescent foci per infected cell, and fluorescence intensity per
infected cell. ZIKV staining was performed similarly, with an additional calculation of the area of
(−)RNA foci.
2.5. Statistical Analyses
Graphs were plotted using Microsoft Excel. For significance testing, GraphPad Prism 6 was used
to perform one-way ANOVA with Dunnett’s post-test for multiple comparisons, comparing each test
condition to a control sample, or Tukey’s post-test for multiple comparisons comparing all conditions
to one another.
3. Results
3.1. RNAscope Permits Simultaneous Imaging of (+) and (−)RNA Strands
As proof of concept for the labelling of (+)RNA and (−)RNA, we chose to use HCV-infected cells,
as HCV is an important human pathogen and one of the most extensively studied (+)RNA viruses.
Furthermore, in their initial description of the RNAscope method, Wang and colleagues showed
the labeling of the HCV (+)RNA, co-labeled with a probe against 18S rRNA [8]. Labeling the less
abundant (−)RNA illustrates the sensitivity of the technique; additionally, (−)RNA is likely a more
faithful marker of RCs than the (+)RNA, as the (−)RNA is thought to serve only one function in the cell,
that of replicative intermediate from which (+)RNA can be synthesized. We fixed infected cells, then
permeabilized and treated with protease to remove some of the proteins that might otherwise obstruct
probe binding in the RC. There was little discernable staining of HCV negative Huh-7.5.1 cells with
either (+)RNA or the (−)RNA probe sets (Figure 2A). By contrast, staining of both strands was apparent
when HCV-infected cells were stained for either (+)RNA or (−)RNA. We then probed for both strands
simultaneously, either (+)RNA then (−)RNA, or (−)RNA then (+)RNA (Figure 2B). We observed
non-overlapping staining in both cases; staining intensity of (+)RNA and (−)RNA appeared similar in
both protocols.
In the course of developing the sequential RNA staining protocol we performed similar staining
with ZIKV-infected cells (Figure 3). We were able to readily stain Zika virus (+)RNA using the same
conditions as HCV, however, to stain ZIKV (−)RNA it was necessary to increase the concentration of
protease used to pre-treat samples from the recommended 1:15 dilution to 1:2. We also found that the
staining of the abundant (+)RNA was consistent independent of single or co-staining, and the order
of staining (Figure 3A,C,D); however, the (−)RNA staining was altered depending on whether the
(−)RNA was stained first or second. Comparing the co-staining shown in Figure 3C,D, (−)RNA staining
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appears to more closely resemble the single staining (−)RNA (Figure 3B) when (−)RNA is stained
before (+)RNA. Staining of uninfected cells demonstrated a high level of specificity, as no foci were seen
(Figure 3E,F). We further examined the conclusion that it is necessary to stain the (−)RNA before the
(+)RNA in order to get reliable labeling of (−)RNA in a co-staining experiment, by quantifying various
parameters of the images and foci. (−)RNA foci were quantified by number, fluorescence intensity,
and size in the co-stained samples and compared to the singly stained (−)RNA samples (Figure 3G–I).
These comparisons again suggested that staining the (−)RNA first in co-staining yields results that are
more consistent with the singly stained samples. When (+)RNA was stained first, there were more
numerous foci and greater intensity, but the foci were smaller. We suspect that the (−)RNA probes may
have been annealing to residual (+)RNA probe. In contrast, the intensity of (+)RNA staining did not
vary depending of the sequence of staining (Figure 3J). Finally, we performed strand-specific RT-qPCR
on the ZIKV RNA to determine the relative abundance of (+)RNA and (−)RNA: we found (+)RNA
was 33-fold
more
than (−)RNA (Table 2).
Viruses 2017,
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Figure 3. Strand-specific bDNA FISH in ZIKV. Vero cells were infected with ZIKV at a multiplicity
of infection (MOI) of 0.1. After 48 h, the cells were fixed and probed for (−)RNA (red) and (+)RNA
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3.2. Staining of Nucleic Acids and Protein in HCV-Infected Cells
order of staining (Figure 3A, C and D); however, the (−)RNA staining was altered depending on
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3.2. Staining of Nucleic Acids and Protein in HCV-Infected Cells
Following establishment of protocols for sequential staining of (−)RNA and (+)RNA, in virus
harboring cells, we additionally stained protein for simultaneous imaging. HCV-infected Huh-7.5.1
cells were stained for RNA and NS5A or core proteins (Figure 4). During the FISH staining, the
proteolytic step was optimized by varying the amount of protease needed to remove sufficient
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protein to expose the RNA for labeling, while retaining sufficient protein for immunofluorescence
labeling in subsequent steps. In principle, this could allow visualization of HCV particles, as the
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3.3. Analysis of Differential Phenotypes of HCV Inhibitors
The sensitivity of these imaging methods permits the study of early events following drug addition.
Cells were infected with HCV, then after 48 h, were treated with DAAs targeting specific viral proteins,
at concentrations 100 times higher than the concentration required to inhibit HCV infection by 50%
(EC50 ). Cells were fixed and examined 8 h after the addition of inhibitors (Figure 5A); this allowed us
to examine the effects of the DAAs on cells with established HCV infection, rather than simply the
loss of virus in newly infected cells. Distinct mechanisms of action were revealed by the effects on
both RNA and protein staining (Figure 5B). Following treatment with NS5A inhibitors, NS5A staining
becomes more concentrated in large aggregations, compared to the more diffuse staining apparent in
the control sample or following treatment with NS3 and NS5B inhibitors. In addition to the change in
NS5A distribution, it appeared that NS5A inhibitors provoked a general reduction in the amounts
of both (+)RNA and (−)RNA, relative to control or treatment with other inhibitors. These data are
consistent with previous reports demonstrating the fast-acting phenotype of NS5A inhibitors [31,44].
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showed the strongest suppression. Compared to other classes of DAA, the NS5A inhibitors appeared
particularly potent at suppressing (−)RNA levels (Figure 5), as all three analyses showed a pronounced
reduction in the (−)RNA with LDV and DCV, that was absent for DNV and SOF at this time point.
These data demonstrate the feasibility of analyzing effects of drugs on strand-specific RNA detection
and replication of RNA viruses at the level of individual cells and single viral RNA molecules. It also
enables differentiation between inhibition of new infections, and effects on cells with on-going viral
replication. Finally, we compared the absolute RNA copy numbers determined for (+)RNA and (−)RNA
by RT-qPCR and bDNA FISH, using the DMSO control data in each case (Figure 5F). The absolute RNA
values were of a comparable order of magnitude to those reported elsewhere [45,46], although the
exact numbers naturally depend heavily on the isolate of HCV and the cell type used, and the efficiency
of the assay method(s). The genome copy numbers determined using RT-qPCR and FISH differed
by approximately five-fold, possibly because the RT-qPCR harvests total RNA while the microscopy
approach counts only the RNA in a single plane, not the complete volume of the cell; however the
ratio of (+)RNA to (−)RNA was the same for the two methods, suggesting that this ratio is reliable.
4. Discussion
Studying the (−)RNA of (+)RNA viruses is particularly challenging, owing to its relatively
low abundance in infected cells [27–29], and the low sensitivity of traditional fluorescent in situ
hybridization imaging techniques when applied to low abundance transcripts [47]. Nevertheless,
understanding the behavior of (−)RNA is of critical importance to elucidating the HCV replication
mechanism, as it is a most critical component of the RC due to its function as the template for the
production of new (+)RNA. Consequently, disruption of the RC may best be understood by study
of the (−)RNA. The low amount of (−)RNA in cells might reflect the limited role it plays in the viral
replication cycle and/or may be a viral strategy to avoid forming dsRNA, a potential inducer of innate
immunity [48–50].
In the current study, we specifically labeled the (−)RNA of HCV, both in singly and dual labeled
infected cells. In addition, we performed cell-level quantitation of the two RNA species, and compare
this imaging-based quantitation to RT-qPCR; we found an approximately five-fold excess of the HCV
(+)RNA by both techniques, consistent with a previous report that used RT-qPCR [27].
In contrast with HCV, ZIKV (+)RNA was so abundant in infected cells that it was not possible to
count foci, making direct comparisons to the abundance of (−)RNA unreliable. We also found that the
ZIKV (−)RNA required more rigorous pre-treatment with protease than HCV (−)RNA to permit FISH
staining. We assume this reflects differences in the nature of the RC, the amount of protein bound,
and accessibility to protease treatment; these properties very likely vary extensively between viruses.
Nevertheless, both bDNA FISH and strand-specific RT-qPCR approaches revealed a large excess of
(+)RNA over (−)RNA in Zika virus-infected cells, comparable to a previous estimate using another
flavivirus, the West Nile virus [51]. Collectively, the data obtained from HCV and ZIKV studies suggest
that RT-qPCR and bDNA FISH are both suitable to follow transcript abundance, however, care must
be taken when comparing transcript numbers, as efficiency of amplification and labelling can vary
significantly between viruses and methods.
It was striking that our ability to detect colocalized RNA strands was extremely limited. In the
case of ZIKV we saw very few (−)RNA strands by bDNA FISH, while in HCV harboring cells, (−)RNA
was reasonably abundant, but rarely colocalized with the (+)RNA signal. As the replication of the
viruses requires transcription of one strand from the other, we would anticipate a certain proportion of
the (+)RNA and (−)RNA signals should colocalize. While we have no single definitive explanation for
the lack of colocalized RNA molecules, there are potential explanations. In the Zika imaging, we found
that it was necessary to increase the concentration of protease. This may indicate that the (−)RNA, in
particular, is sequestered and unavailable for labeling, potentially due to extensive interactions with
the RC. A related potential contributing factor is the extremely high melting temperature reported
for long double-stranded RNA [52–54]. This could lead to a situation where the dsRNA is generally
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refractory to FISH labelling (which requires a single-stranded RNA molecule), reducing the incidence
of apparent colocalization, and reducing the apparent abundance of (−)RNA, a greater proportion of
which is likely to be double-stranded in replication complexes. This interpretation would suggest that
the (−)RNA molecules seen are predominantly “free” single-stranded RNAs; the abundance of this
species may vary greatly between viruses and cell types. Efficient labeling of dsRNA species, such as
may be found in the RC, may require the use of aggressive denaturation to release single-stranded
RNAs for FISH.
An area of particular importance in antiviral research is the mechanism of action of DAAs,
understanding their impact on virus replication and their role in therapeutic regimens. A strength
of this imaging-based technique is to permit analysis of viral RNA and protein in the same cell,
and to select those cells desired for analysis. All DAAs will prevent the spread of infection over
time, irrespective of their specific mechanism, so long as they inhibit some part of the replication
cycle. In contrast to other methods, such as RT-qPCR or Western/Northern blot analyses, which can
phenotypically characterize only mixtures of cell populations, the use of an imaging-based approach
allows us to specifically examine cells that are already infected, and determine how different DAAs
influence on-going viral replication. Recently, we used another imaging-based strategy to assess the
effects of DAAs against HCV by following NS5A staining [31]. Similar to others [44], we were able to
show that the NS5A-targeting drugs have the fastest effect on suppression of viral proteins and total
viral RNA and on redistribution of NS5A. Here, we wished to determine whether staining for viral
RNA could provide additional insights. To this end, we followed the effects of antivirals targeting the
protease, polymerase and NS5A on viral (+) and (−)RNA. We confirmed that the NS5A inhibitors are
the most potent and fast acting inhibitors, both by counting RNA foci per cell and RT-qPCR. Whereas
the extent of (−)RNA suppression was found to be similar with both methods (Figure 5C,E, gray bars),
reductions in the (+)RNA appeared less pronounced when RNA foci per cell were counted. This was
likely due to underestimation of the foci number when a large number of (+)RNA was present (such
as in the DMSO-treated control), leading to underestimating the effect of the inhibitors. As such, the
focus counting approach may be more suited to viruses or conditions where less RNA is present.
As a solution to the difficulties in counting discrete RNA foci, we used an alternative form of
quantification, measuring the total fluorescence in the field of view, expressed per cell. This greatly
improved the consistency of the data, and confirmed that the NS5A inhibitors were particularly
effective at rapidly inhibiting HCV, as we have previously reported [31]. The lack of suppression
by the NS3 inhibitor Danoprevir is not a surprise in this context, given that inhibiting the viral
protease will have a limited impact on the function of extant RCs in the short time frame (8 h) of these
experiments [55,56]. It is noteworthy that the NS5A inhibitors also suppress viral RNA to a greater
extent than Sofosbuvir, a potent inhibitor of the HCV polymerase, NS5B [57]. As the concentration of
Sofosbuvir used should completely inhibit polymerase function, the apparently greater potency of the
NS5A inhibitors as rapid suppressors of the viral RNA is consistent with them functioning through a
distinct or additional mechanism that affects the quantity of viral RNA [32,33,58]; it is possible that
these inhibitors destabilize the RC and hasten the degradation of the viral RNA, particularly the
(−)RNA that is normally protected from nucleases by the RC [59]. This hypothesis is consistent with
the clear disruption of NS5A localization following treatment with the NS5A inhibitors seen in this
study and previously by us and others [31,60].
It has been previously reported that NS5A inhibitors suppress levels of (−)RNA to a greater degree
than the levels of (+)RNA [61]. In our assays we did not observe significant differences in the impact
of NS5A inhibitors on (+) versus (-)RNA. The discordance in the reported results may come from the
disparate timing of the two experiments. The study of Ramanan and colleagues added the inhibitors
20 h post infection [61]; we allowed infection to proceed for 48 h before the addition of inhibitors, as
we were interested in the effects of these inhibitors in the context of an established infection. It is
possible that the sensitivity of (−)RNA to NS5A inhibitors is more pronounced before the infection is
fully established.
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Collectively our data demonstrate the utility of branched DNA in situ hybridization as a tool to
help address questions relating to the biology of RNA viruses. The high sensitivity of bDNA FISH
allows sensitive visualization of incoming viral RNA, before any amplification has taken place, and
early stages of viral genome replication. The ability to select specific cell populations for analysis
enables in-depth investigation of viral RNA strand-specific effects, localization, and interactions
with proteins, owing to the compatibility with immunofluorescence. Thus, this approach may be
particularly suitable, not only to the study of drug mechanisms of action, but also to studies involving
over-expression or silencing of host cell-factors. The high specificity and sensitivity of staining offered
by these methods should help illuminate the critical role of (−)RNA, until now a concealed player in
the biology of (+)RNA viruses.
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